

# Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 22nd January 2025 10-12.30pm

Microsoft Teams Meeting

<b>Present:</b>	Mehrdad Malekian (Chair) Victoria Gemmell (Prof Sec) Kirsty Macfarlane (KM) Rachael Kelly Penny Brankin David Semple (until item Kelly Baillie (item	Gail Richardson Craig Thurtell Tyra Smyth Caroline McLean (item 8b) Mark Barber (item 4c) Sanjiv Nandwani (item 4i)
<b>1. Apologies:</b>	Stephanie Dundas Colin Angus	Alistair Brown
<b>2. Declaration of Interest</b>	nil	

Item	Notes	Action
<b>3.</b>	<b><u>Ratification of minutes of December 2024 meeting</u></b>	RK
	These were agreed as a true reflection of the meeting and can be published.	
<b>4.</b>	<b><u>Matters arising not covered elsewhere on the agenda</u></b>	
a)	<b>Mirikizumab (Omnivoh) Clinical Protocol - Conor Cronin</b> Update awaited.	MM/ VG
b)	<b>Vabysmo Clinical Protocol – Tony Carson (Meena Viridi)</b> Update awaited.	
c)	<b>Acute Stroke – Thrombolysis and Thrombectomy Pathway - Mark Barbour</b> This was discussed and a suggestion made to add the detail relating to dosing in low weight patients as an appendix. Updated copy to be shared with adtc for final approval	
d)	<b>Guidance on Saliva Control in Patients with Motor Neurone Disease - Linda Johnstone</b> Updates made as previously requested. The document was approved and can be shared.	
e)	<b>Paracetamol Guideline – Sarah Brady</b> Updates made as requested, document was approved and can be shared There was a request for this to be shared widely. This will be via Acute Medical Directors for the hospital service, and Prescribing Notes for primary care prescribers.	
f)	<b>Produodopa - Graham McCallum</b> Update awaited	
g)	<b>Use of Tirzepatide in Obesity (Mounjaro) – Izzy Howat</b> This was discussed. A small change around formulary choice for pen needles was requested, and the governance information and change record should be completed. The guideline was approved pending these changes.	
h)	<b>Chicken Pox in pregnancy (Varicella)– Hannah Fulton</b> Changes made as previously requested. The guideline was approved and can be shared.	
	<b>Treatment Pathway-Psoriatic Arthritis– Sanjiv Nandwani</b>	

i)	The committee welcomed this comprehensive document. A query was raised and answered regarding the process for ensuring use of most cost effective choice. A point was also raised regarding addition of these medicines the GP prescribing systems. A small comment clarifying this will be added. The guideline was approved pending these and some small grammatical changes.			
5.	ADTC Committee Business			
	Retiral-Linda Johnstone has stepped down. The committee is appreciative of her service. Replacement-Carol Stewart replaces Josephine Pravinkumar Proposed new Member-Sharon Murray, Acute Director of Nursing. These were accepted. Item raised regarding the need for an additional senior pharmacist for acute services due to the number of acute papers requiring review.			
6,	SMC Advice-CONFIDENTIAL			
6.1	FULL SUBMISSIONS			
	Medicine	Indication in brief	SMC reference	Advice Summary
	lecanemab concentrate for solution for infusion (Leqembi)	Alzheimer’s disease	SMC2700	NOT RECOMMENDED
	cabotegravir prolonged-release suspension for injection and film-coated tablets (Apretude)	PrEP for HIV-1	SMC2718	ACCEPTED RESTRICTED with PAS
	cemiplimab concentrate for solution for infusion (Libtayo)	Recurrent or Metastatic Cervical Cancer	SMC2719	ACCEPTED with PAS
	netarsudil plus latanoprost eye drops solution (Roclanda)	Open-Angle Glaucoma	SMC2720	ACCEPTED RESTRICTED
	fenfluramine oral solution (Fintepla)	Lennox-Gastaut syndrome - Epilepsy	SMC2723	ACCEPTED RESTRICTED with PAS
	ABBREVIATED SUBMISSIONS			
	Medicine	Indication in brief	SMC reference	Advice Summary
	durvalumab 50 mg/mL concentrate for solution for infusion (Imfinzi)	Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	SMC2734	ACCEPTED with PAS

	<div> <div>olaparib 150 mg film-coated tablets (Lynparza)</div> <div>Breast Cancer</div> <div>SMC2737</div> <div>ACCEPTED with PAS</div> </div> <p><b>daratumumab (Darzalex)</b></p> <p>The Marketing Authorisation for daratumumab (Darzalex) has been extended to include use, in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. SMC has previously issued advice for daratumumab in combination with bortezomib, thalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (<a href="#">SMC2302 daratumumab (Darzalex)</a>). SMC will not review this minor change to the indication.</p> <p><b>These will be shared with relevant specialists for feedback regarding use in NHSL.</b></p> <p><b>FOR INFORMATION</b></p> <p><b>Note: Budget Impact templates will be sent to NHS Board contacts and Directors of Pharmacy under separate cover.</b></p>	
6.2	<p><b>Updates to NHSL status on SMC advice AND ADTC NEW MEDICINES DECISIONS</b></p> <p>RK outlined designation updates for pending medicines as per protocols discussed at Dec 2024 meeting and following publication of SACT protocols.</p> <p>RK raised with the committee a number of medicines which have surpassed the 90-day deadline and are still in a pending state, including Rimegepant and Symbicort.</p> <p>Designation updates were discussed for medicines that have passed deadline for which no feedback/communication was received – Linzagolix.</p> <p>RK raised medicines which had passed deadline for which protocols/updated guidelines were expected imminently, including Vabysmo, Lebrikizumab, Somapacitan.</p>	
7.	<b><u>Lanarkshire Formulary / West of Scotland Formulary</u></b>	
7.1	This was agreed. Included updating out of stock information, Drug Tariff information within Chapter 7, and removing & updating old broken hyperlinks. Proposal to remove information pertaining to the national shortage of alteplase and tenecteplase was agreed.	
7.2	<p><b><u>West of Scotland Formulary Updates</u></b></p> <p>GB gave a progress update. No concerns raised.</p>	
8	<b><u>Clinical Protocols &amp; Guidelines</u></b>	
a)	<p><b>Hypocalcaemia-Frieda Campbell (Ruth Waters)</b></p> <p>Some small changes requested around formulary choices. Approved pending these changes.</p>	
b)	<p><b>HDAT Guideline update 2024-Caroline McLean</b></p> <p>CM gave an overview of this updated version of an existing guideline. Some welcome additions were noted. A query was discussed regarding addition to GP prescribing system as a repeat item. It was agreed that this was necessary to ensure addition of the item to the ECS list. A briefing note will be designed to cover this by MH Pharmacy team. The document is ratified pending this clarification.</p>	
c)	<p><b>Lidocaine Plasters for Palliative Care Indications-Monitoring Record-Linda Johnstone</b></p> <p>Approved for use in palliative care only.</p> <p>A comment was made around high usage despite limited evidence. Work is underway to tackle this in both acute and primary care.</p> <p>The document was approved with no changes.</p>	

	<p><b>d) Hypertensive Disorders in Pregnancy - Hannah Fulton</b> TS will share with GP sub and feedback, however the committee agreed to approve pending some small typographical corrections.</p> <p><b>e) Risankizumab for Ulcerative Colitis - Conor Cronin</b> This was accepted on clinical grounds, but will need to pass through the usual channels for cost and operational approval. The group also felt it would be helpful to update the current pathway to include this. Final approval is pending approval of the updated pathway. Date on document to be amended</p>	
<b>9.</b>	<b><u>New Medicine Safety Notifications &amp; Alerts</u></b>	<b>GRB</b>
<b>9.a</b>	<p><b>Shortage of Pancreatic enzyme replacement therapy (PERT)</b> Update to previous alert. To confirm actions are in hand with CM. <b>POST MEETING NOTE:</b>CM confirmed all actions are complete. Local mitigation plans remain in place and no concerns raised. Point raised regarding communication of Drug Alerts. GRB will take this forward.</p>	
<b>10.</b>	<b><u>Prescribing Management Board Update</u></b>	
<p><b>10.1</b></p> <p><b>10.2</b></p>	<p><b>PMB report</b> Rota of Acute non-cancer/acute cancer/ primary care / mental health Plans for this are ongoing</p> <p><b>PMB SMC decision business cases</b> Requires new form to link across ADTC, clinical, finance &amp; service Plans for this are ongoing</p>	
<b>11.</b>	<b><u>Medicines for the Treatment of Cancer</u></b>	
<p><b>a.</b></p> <p><b>b.</b></p>	<p><b>West of Scotland Cancer Network Prescribing Advisory Subgroup-Summary to Boards Dec 2024 and papers</b> KB gave an update on the WoSCAN summary for Boards Dec 2204. These were accepted.</p> <p><b>NCMAG Advice timeline change</b> This was noted</p>	
<b>12.</b>	<b><u>Non-Medical Prescribing</u></b>	
<b>a.</b>	<p><b>Symptomatic Relief Policy</b> The current policy is due for revision and update. Views are being sought on potential changes, including the ongoing need for it. The committee agreed that it remains necessary, especially for off-site bed areas.</p>	
<b>13.</b>	<b><u>PGD Activity Report</u></b>	
<b>a.</b>	<p><b>PGD Process Document</b> KM gave an overview of the updated policy and template. It has been redesigned as a guideline, will be available on the RDS website, and is underpinned by appropriate governance. It was approved with no changes and can be shared. Update given regarding previously identified out of date PGD's. KM will liaise with acute site Pharmacy HOD's and Director of NMAHP regarding this and plans to rectify.</p>	
<b>14.</b>	<b><u>Antimicrobial Management Team Update</u></b>	

	<p><b>a. Antimicrobial Guidance SBAR - Claire MacDonald</b> This was approved and the website can be updated.</p> <p><b>b. Piperacillin/tazobactam (Tazocin) – Gary Lynas</b> The committee agreed the content was helpful, however should be transferred to the standard guideline template and include governance information.</p> <p><b>c. Pylera SBAR 2025 – Steve McCormick</b> The use of Pylera was approved and can be added to the formulary.</p>	
15.	<b><u>Lay member related items</u></b>	
	nil	
	<b><u>AOCB</u></b>	
	<p><b>a.</b> KM raised an issue regarding the Adult Risk Assessment for VTE that is contained within the current acute admissions booklet. The individual risk assessment is available on FirstPort website, but the governance supporting the addition of this is not clear. There is conflicting advice on dosing of LMWH. This will be escalated via Acute Clinical Governance Group and risk Management Group. Additionally, KM will liaise with MM regarding further actions.</p> <p><b>b.</b> Clinical Labs have changed the ranges for reporting of LFT's. This means that any guidelines that contain treatment guidance in the context of LFT's will need updated. The communication of this change will be raised at the Acute Clinical Governance Group.</p>	
17.	<p><b><u>Date of next meeting</u></b>  Wednesday 19<sup>th</sup> February 2025 10-12.30pm  MS TEAMS</p>	